Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,446 shares of the biopharmaceutical company’s stock after selling 34,741 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Gilead Sciences were worth $4,573,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. SteelPeak Wealth LLC bought a new stake in shares of Gilead Sciences in the third quarter worth $1,729,000. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $1,189,000. Larson Financial Group LLC grew its stake in shares of Gilead Sciences by 15.0% in the 3rd quarter. Larson Financial Group LLC now owns 1,199 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 156 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its position in Gilead Sciences by 3.6% during the third quarter. Nomura Asset Management Co. Ltd. now owns 892,113 shares of the biopharmaceutical company’s stock worth $66,855,000 after purchasing an additional 31,032 shares during the period. Finally, STF Management LP boosted its position in Gilead Sciences by 156.5% during the third quarter. STF Management LP now owns 20,388 shares of the biopharmaceutical company’s stock worth $1,528,000 after purchasing an additional 12,438 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research note on Wednesday, April 24th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Maxim Group cut their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Finally, Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Trading Up 0.8 %

Shares of Gilead Sciences stock traded up $0.51 during trading hours on Wednesday, hitting $67.80. The company’s stock had a trading volume of 6,221,165 shares, compared to its average volume of 7,269,121. Gilead Sciences, Inc. has a 1-year low of $64.33 and a 1-year high of $87.86. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $84.47 billion, a PE ratio of 188.36, a P/E/G ratio of 1.37 and a beta of 0.22. The business has a fifty day moving average of $68.93 and a 200 day moving average of $74.75.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same quarter last year, the firm earned $1.37 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.54%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.